Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects

Triple negative breast cancer (TNBC) portraying deficient expression of estrogen receptor (ER), progesterone receptor (PR) and Human epidermal growth factor receptor 2 (HER2) is known to be the most aggressive subtype associated with poor prognosis and interventional strategies limited to chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Khadela, Avinash, Soni, Shruti, Megha, Kaivalya, Shah, Aayushi C., Pandya, Aanshi J., Kothari, Nirjari, Shah, Ishika, Avinash, C. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751516/
https://www.ncbi.nlm.nih.gov/pubmed/36520261
http://dx.doi.org/10.1007/s12032-022-01922-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751516/
https://www.ncbi.nlm.nih.gov/pubmed/36520261
http://dx.doi.org/10.1007/s12032-022-01922-6

Ejemplares similares